Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kevin Gregory-Evans is active.

Publication


Featured researches published by Kevin Gregory-Evans.


American Journal of Human Genetics | 2004

Mutations in LRP5 or FZD4 Underlie the Common Familial Exudative Vitreoretinopathy Locus on Chromosome 11q

Carmel Toomes; Helen M. Bottomley; Richard M. Jackson; Katherine V. Towns; Sheila Scott; David A. Mackey; Jamie E. Craig; Li Jiang; Zhenglin Yang; Richard C. Trembath; Geoffrey Woodruff; Cheryl Y. Gregory-Evans; Kevin Gregory-Evans; Michael J. Parker; Graeme C.M. Black; Louise Downey; Kang Zhang; Chris F. Inglehearn

Familial exudative vitreoretinopathy (FEVR) is an inherited blinding disorder of the retinal vascular system. Autosomal dominant FEVR is genetically heterogeneous, but its principal locus, EVR1, is on chromosome 11q13-q23. The gene encoding the Wnt receptor frizzled-4 (FZD4) was recently reported to be the EVR1 gene, but our mutation screen revealed fewer patients harboring mutations than expected. Here, we describe mutations in a second gene at the EVR1 locus, low-density-lipoprotein receptor-related protein 5 (LRP5), a Wnt coreceptor. This finding further underlines the significance of Wnt signaling in the vascularization of the eye and highlights the potential dangers of using multiple families to refine genetic intervals in gene-identification studies.


Current Biology | 2007

Short-Wavelength Light Sensitivity of Circadian, Pupillary, and Visual Awareness in Humans Lacking an Outer Retina

F H Zaidi; Joseph T. Hull; Stuart N. Peirson; Katharina Wulff; Daniel Aeschbach; Joshua J. Gooley; George C. Brainard; Kevin Gregory-Evans; Joseph F. Rizzo; Charles A. Czeisler; Russell G. Foster; Merrick J. Moseley; Steven W. Lockley

Summary As the ear has dual functions for audition and balance, the eye has a dual role in detecting light for a wide range of behavioral and physiological functions separate from sight [1–11]. These responses are driven primarily by stimulation of photosensitive retinal ganglion cells (pRGCs) that are most sensitive to short-wavelength (∼480 nm) blue light and remain functional in the absence of rods and cones [8–10]. We examined the spectral sensitivity of non-image-forming responses in two profoundly blind subjects lacking functional rods and cones (one male, 56 yr old; one female, 87 yr old). In the male subject, we found that short-wavelength light preferentially suppressed melatonin, reset the circadian pacemaker, and directly enhanced alertness compared to 555 nm exposure, which is the peak sensitivity of the photopic visual system. In an action spectrum for pupillary constriction, the female subject exhibited a peak spectral sensitivity (λmax) of 480 nm, matching that of the pRGCs but not that of the rods and cones. This subject was also able to correctly report a threshold short-wavelength stimulus (∼480 nm) but not other wavelengths. Collectively these data show that pRGCs contribute to both circadian physiology and rudimentary visual awareness in humans and challenge the assumption that rod- and cone-based photoreception mediate all “visual” responses to light.


Journal of Medical Genetics | 2004

Ocular coloboma: a reassessment in the age of molecular neuroscience

Cheryl Y. Gregory-Evans; M J Williams; S Halford; Kevin Gregory-Evans

Congenital colobomata of the eye are important causes of childhood visual impairment and blindness. Ocular coloboma can be seen in isolation and in an impressive number of multisystem syndromes, where the eye phenotype is often seen in association with severe neurological or craniofacial anomalies or other systemic developmental defects. Several studies have shown that, in addition to inheritance, environmental influences may be causative factors. Through work to identify genes underlying inherited coloboma, significant inroads are being made into understanding the molecular events controlling closure of the optic fissure. In general, severity of disease can be linked to the temporal expression of the gene, but this is modified by factors such as tissue specificity of gene expression and genetic redundancy.


Ophthalmology | 2000

Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase

Kevin Gregory-Evans; Rosemary E. Kelsell; Cheryl Y. Gregory-Evans; Susan M. Downes; Fred W. Fitzke; Graham E. Holder; Matthew P. Simunovic; J. D. Mollon; Rachel M. Taylor; David M. Hunt; Alan C. Bird; Anthony T. Moore

OBJECTIVE To describe the clinical features of autosomal dominant cone-rod retinal dystrophy (CRD) in a British family mapping to chromosome 17p12-p13 (CORD6), with a heterozygous mutation (Glu837Asp/ Arg838Ser) of GUCY2D. DESIGN A prospective, clinical family survey. PATIENTS Ten affected members of a family with autosomal dominant CRD. METHODS Full clinical examinations were undertaken. Selected affected family members underwent electrophysiologic evaluation, scotopic static perimetry, dark adaptometry, and color vision assessment. MAIN OUTCOME MEASURES Clinical appearance and electroretinographic responses. RESULTS Typical clinical and electroretinographic features of childhood-onset CRD were recorded. In addition, moderate myopia and pendular nystagmus were seen in affected individuals. Color vision assessment in the youngest affected individual showed no color discrimination on a tritan axis, but retention of significant red-green discrimination. Electronegative electroretinogram responses were seen on electrophysiology in the only young family member examined. CONCLUSIONS The phenotype associated with GUCY2D CRD is clinically distinct from that associated with other dominant CRD loci. Unusual electroretinographic responses may indicate that this mutation of GUCY2D is associated with early defects in photoreceptor synaptic transmission to second-order neurons.


Cell Transplantation | 2012

Focused Magnetic Stem Cell Targeting to the Retina Using Superparamagnetic Iron Oxide Nanoparticles

Anat Yanai; Urs O. Häfeli; Andrew Metcalfe; Peter Soema; Lois Addo; Cheryl Y. Gregory-Evans; Kelvin Po; Xianghong Shan; Orson L. Moritz; Kevin Gregory-Evans

Developing new ways of delivering cells to diseased tissue will be a key factor in translating cell therapeutics research into clinical use. Magnetically targeting cells enables delivery of significant numbers of cells to key areas of specific organs. To demonstrate feasibility in neurological tissue, we targeted cells magnetically to the upper hemisphere of the rodent retina. Rat mesenchymal stem cells (MSCs) were magnetized using superparamagnetic iron oxide nanoparticles (SPIONs). In vitro studies suggested that magnetization with fluidMAG-D was well tolerated, that cells remained viable, and they retained their differentiation capabilities. FluidMAG-D-labeled MSCs were injected intravitreally or via the tail vein of the S334ter-4 transgenic rat model of retinal degeneration with or without placing a gold-plated neodymium disc magnet within the orbit, but outside the eye. Retinal flatmount and cryosection imaging demonstrated that after intravitreal injection cells localized to the inner retina in a tightly confined area corresponding to the position of the orbital magnet. After intravenous injection, similar retinal localization was achieved and remarkably was associated with a tenfold increase in magnetic MSC delivery to the retina. Cryosections demonstrated that cells had migrated into both the inner and outer retina. Magnetic MSC treatment with orbital magnet also resulted in significantly higher retinal concentrations of anti-inflammatory molecules interleukin-10 and hepatocyte growth factor. This suggested that intravenous MSC therapy also resulted in significant therapeutic benefit in the dystrophic retina. With minimal risk of collateral damage, these results suggest that magnetic cell delivery is the best approach for controlled delivery of cells to the outer retina—the focus for disease in age-related macular degeneration and retinitis pigmentosa.


American Journal of Human Genetics | 1998

Localization of a gene (CORD7) for a dominant cone-rod dystrophy to chromosome 6q

Rosemary E. Kelsell; Kevin Gregory-Evans; Cheryl Y. Gregory-Evans; Graham E. Holder; Marcelle Jay; Bernhard H. F. Weber; Anthony T. Moore; Alan C. Bird; David M. Hunt

We thank the family members for their cooperation in this study. This work was supported by the Wellcome Trust (grant 041905), the Frost Charitable Trust, and the Foundation Fighting Blindness.


Experimental Eye Research | 2003

Expression of opsin genes early in ocular development of humans and mice.

Emma E. Tarttelin; James Bellingham; Lindsay C. Bibb; Russell G. Foster; Mark W. Hankins; Kevin Gregory-Evans; Cheryl Y. Gregory-Evans; Dominic J. Wells; Robert J. Lucas

We have compared the onsets of expression of the classical visual opsins with those of the non-rod, non-cone opsins in foetal and post-natal eye tissue from mice and humans. Mouse Rgr-opsin, peropsin, encephalopsin and melanopsin are all expressed in foetal development by E11.5, unlike the murine rod and cone opsins that exhibit post-natal expression, e.g. P1 for ultraviolet cone opsin and P5 for rod opsin. Human non-rod, non-cone opsins are also all expressed early, by 8.6 weeks post-conception. The implications of these observations are discussed with regard to the possible functions of these opsins at early stages of ocular development.


Trends in Genetics | 1998

Genetic blindness: current concepts in the pathogenesis of human outer retinal dystrophies

Kevin Gregory-Evans; Shomi S. Bhattacharya

Outer retinal dystrophies are the major causes of incurable blindness in the Western world. Understanding the etiology of retinal dystrophies has improved remarkably over the past decade. A number of genes, such as RHO, PDE-beta, RDS, TIMP3, MYO7A, RETGC1, RPGR, CRX and ABCR, are now known to be particularly important. Characterization of the genetic basis for disease is leading to new concepts of pathogenesis at the molecular and cellular levels. Such detailed understanding of disease processes is also stimulating a renewed interest in therapeutic strategies.


Journal of Clinical Investigation | 2014

Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects

Cheryl Y. Gregory-Evans; Xia Wang; Kishor M. Wasan; Jinying Zhao; Andrew Metcalfe; Kevin Gregory-Evans

Aniridia is a congenital and progressive panocular condition with poor visual prognosis that is associated with brain, olfactory, and pancreatic abnormalities. Development of aniridia is linked with nonsense mutations that result in paired box 6 (PAX6) haploinsufficiency. Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye. We focused on the nonsense suppression drugs 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin. Remarkably, we demonstrated that nonsense suppression not only inhibited disease progression but also stably reversed corneal, lens, and retinal malformation defects and restored electrical and behavioral responses of the retina. The most successful results were achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 80, 1% powdered ataluren, 1% carboxymethylcellulose), which was designed to enhance particle dispersion and to increase suspension viscosity. These observations suggest that the eye retains marked developmental plasticity into the postnatal period and remains sensitive to molecular remodeling. Furthermore, these data indicate that other neurological developmental anomalies associated with dosage-sensitive genetic mutations may be reversible through nonsense suppression therapeutics.


American Journal of Medical Genetics Part A | 2004

Ocular coloboma and high myopia with Hirschsprung disease associated with a novel ZFHX1B missense mutation and trisomy 21.

Cheryl Y. Gregory-Evans; H. Vieira; R. Dalton; G.G.W. Adams; Alison Salt; Kevin Gregory-Evans

Syndromic Hirschsprung disease has been associated with mutations in ZFHX1B, a Smad‐interacting transcriptional repressor protein. Tissue in situ hybridization has demonstrated strong expression of ZFHX1B in the developing eye, suggesting that some mutations in this gene may cause visual loss. However, none of the reported mutations have been associated with an ocular phenotype. We describe a patient with Down syndrome and Hirschsprung disease with high myopia and ocular coloboma affecting the iris and retina. In addition to trisomy 21, a novel, de novo heterozygous A to G transition in exon 8 of the ZFHX1B gene was identified, which results in a R953G amino acid substitution. This abnormality was not seen in a screen of 200 chromosomes from ethnically matched, normal controls. The arginine residue at position 953 is an extremely conserved amino acid throughout evolution. This is the first report associating Hirschsprung disease and severe eye defects with a specific genetic mutation and is the first report of a mutation in ZFHX1B causing a developmental ocular anomaly.

Collaboration


Dive into the Kevin Gregory-Evans's collaboration.

Top Co-Authors

Avatar

Cheryl Y. Gregory-Evans

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Andrew Metcalfe

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Anat Yanai

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher Laver

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Orson L. Moritz

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Xianghong Shan

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mariya Moosajee

UCL Institute of Ophthalmology

View shared research outputs
Researchain Logo
Decentralizing Knowledge